DKK296.2 2.7 0.9%
Last Trade - 16/04/21
| Market Cap | £2.20bn |
| Enterprise Value | £2.39bn |
| Revenue | £215.8m |
| Position in Universe | 220th / 1831 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,021 | 1,007 | 1,370 | 500.6 | 662.5 | 1,852 | 2,158 | 2,671 | +12.7% | ||
| +143.8 | -33.3 | +282.6 | ||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | July 1, 1992 |
| Public Since | November 2, 1998 |
| No. of Shareholders: | 69,640 |
| No. of Employees: | 475 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange - Copenhagen |
| Shares in Issue | 63,684,407 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Philip Heymans Alle 3, HELLERUP, 2900, Denmark |
| Web | http://www.bavarian-nordic.com |
| Phone | + |
| Contact | Rolf Soerensen (Vice President Investor Relations & Communications) |
| Auditors | Deloitte Statsautoriseret Revisionspartnerselskab |
As of 16/04/21, shares in Bavarian Nordic A/S are trading at DKK296.2, giving the company a market capitalisation of £2.20bn. This share price information is delayed by 15 minutes.
Shares in Bavarian Nordic A/S are currently trading at DKK296.2 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bavarian Nordic A/S price has moved by 65.6% over the past year.
Of the analysts with advisory recommendations for Bavarian Nordic A/S, there are there are currently 3 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bavarian Nordic A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Bavarian Nordic A/S is scheduled to issue upcoming financial results on the following dates:
Bavarian Nordic A/S does not currently pay a dividend.
Bavarian Nordic A/S does not currently pay a dividend.
Bavarian Nordic A/S does not currently pay a dividend.
To buy shares in Bavarian Nordic A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bavarian Nordic A/S are currently trading at DKK296.2, giving the company a market capitalisation of £2.20bn.
Here are the trading details for Bavarian Nordic A/S:
Based on an overall assessment of its quality, value and momentum, Bavarian Nordic A/S is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bavarian Nordic A/S are currently priced at DKK296.2. At that level they are trading at 6.05% discount to the analyst consensus target price of 0.00.
Analysts covering Bavarian Nordic A/S currently have a consensus Earnings Per Share (EPS) forecast of -2.393 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bavarian Nordic A/S. Over the past six months, the relative strength of its shares against the market has been 33.84%. At the current price of DKK296.2, shares in Bavarian Nordic A/S are trading at 40.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bavarian Nordic A/S PE ratio based on its reported earnings over the past 12 months is 50.32. The shares are currently trading at DKK296.2.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bavarian Nordic A/S's management team is headed by:
Here are the top five shareholders of Bavarian Nordic A/S based on the size of their shareholding:
